Table 1.
Correlation between GPI expression and the clinicopathological features of the BRCA cases.
| Characteristic | Low expression of GPI | High expression of GPI | p |
|---|---|---|---|
| n | 541 | 542 | |
| T stage, n (%) | 0.004 | ||
| T1 | 156 (14.4%) | 121 (11.2%) | |
| T2 | 293 (27.1%) | 336 (31.1%) | |
| T3 | 79 (7.3%) | 60 (5.6%) | |
| T4 | 12 (1.1%) | 23 (2.1%) | |
| N stage, n (%) | 0.154 | ||
| N0 | 246 (23.1%) | 268 (25.2%) | |
| N1 | 185 (17.4%) | 173 (16.3%) | |
| N2 | 54 (5.1%) | 62 (5.8%) | |
| N3 | 46 (4.3%) | 30 (2.8%) | |
| M stage, n (%) | 0.340 | ||
| M0 | 436 (47.3%) | 466 (50.5%) | |
| M1 | 7 (0.8%) | 13 (1.4%) | |
| Pathologic stage, n (%) | 0.199 | ||
| Stage I | 97 (9.2%) | 84 (7.9%) | |
| Stage II | 296 (27.9%) | 323 (30.5%) | |
| Stage III | 131 (12.4%) | 111 (10.5%) | |
| Stage IV | 7 (0.7%) | 11 (1%) | |
| Race, n (%) | 0.049 | ||
| Asian | 22 (2.2%) | 38 (3.8%) | |
| Black or African American | 85 (8.6%) | 96 (9.7%) | |
| White | 391 (39.3%) | 362 (36.4%) | |
| Age, n (%) | 0.016 | ||
| ≤60 | 280 (25.9%) | 321 (29.6%) | |
| >60 | 261 (24.1%) | 221 (20.4%) | |
| Histological type, n (%) | <0.001 | ||
| Infiltrating ductal carcinoma | 340 (34.8%) | 432 (44.2%) | |
| Infiltrating lobular carcinoma | 152 (15.6%) | 53 (5.4%) | |
| PR status, n (%) | <0.001 | ||
| Negative | 127 (12.3%) | 215 (20.8%) | |
| Indeterminate | 1 (0.1%) | 3 (0.3%) | |
| Positive | 387 (37.4%) | 301 (29.1%) | |
| ER status, n (%) | <0.001 | ||
| Negative | 77 (7.4%) | 163 (15.7%) | |
| Indeterminate | 0 (0%) | 2 (0.2%) | |
| Positive | 438 (42.3%) | 355 (34.3%) | |
| HER2 status, n (%) | 0.482 | ||
| Negative | 264 (36.3%) | 294 (40.4%) | |
| Indeterminate | 7 (1%) | 5 (0.7%) | |
| Positive | 68 (9.4%) | 89 (12.2%) | |
| PAM50, n (%) | <0.001 | ||
| Normal | 33 (3%) | 7 (0.6%) | |
| LumA | 354 (32.7%) | 208 (19.2%) | |
| LumB | 83 (7.7%) | 121 (11.2%) | |
| HER2 | 21 (1.9%) | 61 (5.6%) | |
| Basal | 50 (4.6%) | 145 (13.4%) | |
| Menopause status, n (%) | 0.445 | ||
| Pre | 108 (11.1%) | 121 (12.4%) | |
| Peri | 22 (2.3%) | 18 (1.9%) | |
| Post | 362 (37.2%) | 341 (35.1%) | |
| Anatomic neoplasm subdivisions, n (%) | 0.153 | ||
| Left | 269 (24.8%) | 294 (27.1%) | |
| Right | 272 (25.1%) | 248 (22.9%) | |
| Radiation therapy, n (%) | 0.092 | ||
| No | 208 (21.1%) | 226 (22.9%) | |
| Yes | 296 (30%) | 257 (26%) | |
| Age, median (IQR) | 60 (50, 67) | 56 (47, 67) | 0.027 |
PR, progesterone receptor; ER, estrogen receptor; IQR, interquartile range.